Minovia Therapeutics

Minovia Therapeutics is committed to becoming the global leader in developing novel mitochondrial cell therapies to treat patients with mitochondrial diseases. Every day, Minovia Therapeutics collaborates with the world’s leading scientists, clinicians, and patient groups to transform mitochondrial science into meaningful therapies for mitochondrial diseases – from rare to more common conditions. As an international mitochondrial therapeutics company, Minovia Therapeutics aims to rapidly change patients' lives through biotechnology. Following a compassionate use case of our proprietary mitochondrial augmentation therapy at Israel's Sheba Medical Center, Minovia Therapeutics is now conducting the first clinical trial for Pearson syndrome, an extremely rare pediatric disease.